Cognitive decline among older people and Alzheimer's disease (AD), the specific condition most frequently responsible for severe decline in this age group, are large and growing humanistic and public health problems. This trajectory is a human trait with a heritable component, but is also associated with non-genetic factors. We propose to explore the architecture of the phenotype of decline in global cognition to inform the functional characterization of both known and novel risk factors. Since the decline in cognition may not follow a linear trend, we will compare the performance of multiple statistical models with which to examine this trait, starting with a linear mixed effects model and moving to models of increasing complexity, including penalized and quadratic spline models. Using the optimal statistical model determined in these efforts, we will explore the relationship between this enhanced estimate of cognitive trajectories with existing sets of data cataloguing (1) genome-wide genotype data and (2) genome-wide DNA methylation profiles of the dorsolateral prefrontal cortex from the same individuals. In addition, these estimates of cognitive decline will also be examined for associations with a novel dataset of microRNA (miRNA) profiles from the same region of the brain in the same subjects. Further, limiting our analyses to DNA methylation and miRNA features associated with cognitive decline, we will assess for evidence of interaction in these two types of measures, which capture different aspects of the transcriptional state of the brain. While examining genetic, methylomic and transcriptomic factors separately is important, informative results will also come from assessing how they all work together to affect cognition. Therefore, we propose to use model reduction techniques, such as LASSO, to create a comprehensive model of cognitive decline that incorporates non-redundant clinical, neuropathologic, genetic, DNA methylation and miRNA features that are risk factors for cognitive decline. We will start with the known clinical and genetic components and then consider genomic, DNA methylation and miRNA traits discovered in earlier analyses in this proposal. Throughout this proposal, we will produce integrated models of known and new risk factors that relate to the genetic architecture of cognitive decline, and secondarily to AD. Ultimately, these models will provide an ideal basis for developing new studies and analytic plans that will drive my own career as an independent investigator. Moreover, many leads will certainly emerge from these studies, the pursuit of which will serve to further my career by creating additional funding opportunities.

Public Health Relevance

The goal of this proposal is to understand the genomic, epigenomic and transcriptomic architecture of cognitive decline. In understanding how this variation affects aging and human cognitive function will allow investigators to better understand the onset of cognitive decline and diseases of cognition, such as AD. This may help to develop new treatments to delay and hopefully prevent onset of Alzheimer's disease and cognitive decline, and to develop clinical tests that may be able to predict who is at risk of developing Alzheimer's disease and cognitive decline.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Mentored Quantitative Research Career Development Award (K25)
Project #
5K25AG041906-02
Application #
8526342
Study Section
National Institute on Aging Initial Review Group (NIA)
Program Officer
Wagster, Molly V
Project Start
2012-08-15
Project End
2017-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
2
Fiscal Year
2013
Total Cost
$154,170
Indirect Cost
$11,420
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Yang, Hyun-Sik; Yu, Lei; White, Charles C et al. (2018) Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ?4 haplotype status: a community-based cohort study. Lancet Neurol 17:773-781
De Jager, Philip L; Ma, Yiyi; McCabe, Cristin et al. (2018) A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Sci Data 5:180142
Chibnik, L B; White, C C; Mukherjee, S et al. (2018) Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies. Mol Psychiatry 23:1521-1529
Bove, Riley M; Patrick, Ellis; Aubin, Cristin McCabe et al. (2018) Reproductive period and epigenetic modifications of the oxidative phosphorylation pathway in the human prefrontal cortex. PLoS One 13:e0199073
Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998
Bargiela, David; Bianchi, Matthew T; Westover, M Brandon et al. (2017) Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology 88:677-684
Felsky, Daniel; Xu, Jishu; Chibnik, Lori B et al. (2017) Genetic epistasis regulates amyloid deposition in resilient aging. Alzheimers Dement 13:1107-1116
Patrick, Ellis; Rajagopal, Sathyapriya; Wong, Hon-Kit Andus et al. (2017) Dissecting the role of non-coding RNAs in the accumulation of amyloid and tau neuropathologies in Alzheimer's disease. Mol Neurodegener 12:51
Yang, Hyun-Sik; White, Charles C; Chibnik, Lori B et al. (2017) UNC5C variants are associated with cerebral amyloid angiopathy. Neurol Genet 3:e176
Chibnik, Lori B; Wolters, Frank J; Bäckman, Kristoffer et al. (2017) Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. Eur J Epidemiol 32:931-938

Showing the most recent 10 out of 51 publications